Praetorian update: aresa has not yet obtained guarantee of a capital increase.

The independent analysis provider, Praetorian Research has published their
latest update regarding aresa, and states: 

Kill or cure

aresa has not yet obtained guarantee of a capital increase. If such guarantee
is not obtained by end of December aresa will cease operations. Even if aresa
needs to obtain guarantees for only DKK 10m the probability of success is
small, as obviously time is running out and capital markets remain sluggish. We
assess aresa's cash balance at DKK 7m in case of liquidation, equal to DKK 2.9
per share. 

The entire analysis can be found in the attached document.

For more information, please contact Jesper Ilsøe, Praetorian Research, tlf:
+45 5025 3000, email: info@p-research.dk 

or                                                                              

Steen Thaarup                                                                   
CEO                                                                             

Phone: +45 7022 7747                                                            
Mobile: +45 4077 8695                                                           
E-mail: st@aresa.dk                                                             

The company's certified advisor is Dahl-Sørensen & Partners A/S, Allan Reimann, 
tel.: +45 3364 9205.                                                            


About Aresa                                                                    
Aresa is originally a plant biotech company established in 2001 as an
off-spring from the Institute of Molecular Biology at Copenhagen University. 

Aresa wants to focus on the development of mine affected soil to productive
use. 

Aresa shares are traded at the Nasdaq/OMX-First North stock exchange since the  
introduction in 2006. Aresa is based at Symbion Science Park in Copenhagen and  
has two subsidiaries in Croatia and Serbia.